In a twist worthy of a Silicon Valley soap opera, Apple has scored a peculiar victory in its ongoing patent battle with medical device maker Masimo. A federal jury recently ruled that Masimo had indeed infringed on some of Apple’s smartwatch patents. However, the damages awarded to Apple for this infringement were a mere $250.

Yes, you read that right. A quarter of a thousand dollars.

While this might seem like a paltry sum for a tech giant like Apple, it’s important to understand the context. This isn’t about the money. Instead, it’s about a symbolic win, a legal victory that could have far-reaching implications for the future of wearable tech.

The dispute between Apple and Masimo has been a long and winding road. Both companies are giants in their respective fields, but their clash has often felt like a David and Goliath battle, with Apple as the mighty Goliath and Masimo as the scrappy underdog.

Masimo, known for its innovative medical devices, has accused Apple of infringing on its pulse oximetry patents. Pulse oximetry is a technology that measures blood oxygen levels, a crucial metric for health monitoring. Apple has incorporated this technology into its Apple Watch, a device that has revolutionized the wearable tech industry.

Earlier this year, Apple faced a significant setback when the International Trade Commission ruled in favor of Masimo, ordering a ban on the import of certain Apple Watch models that infringed on Masimo’s patents. This forced Apple to remove blood oxygen monitoring features from its latest smartwatch models in the US.

The recent jury verdict, while a victory for Apple, is a bittersweet one. The paltry damages awarded underscore the limitations of the legal system in addressing complex patent disputes. It also highlights the challenges that tech companies face in protecting their intellectual property, especially in the fast-paced world of wearable technology.